Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chelation therapy Clear all
Completed Phase 2 Interventional Results available

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

NCT00419770
View directory record Official record
Conditions
Mucormycosis
Interventions
deferasirox, Placebo, Liposomal amphotericin B
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

NCT00171210
View directory record Official record
Conditions
Transfusional Iron Overload in β-thalassemia
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 25, 2026, 8:08 AM EDT
Completed No phase listed Observational

Sickle Cell Disease: A Retrospective Chart Review

NCT01441375
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Orleans, Louisiana • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

NCT04269889
View directory record Official record
Conditions
Anemia, Diamond-Blackfan
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

NCT00940602
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deferasirox, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

NCT01059474
View directory record Official record
Conditions
Toxicity
Interventions
transdermal DMPS
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

NCT01186419
View directory record Official record
Conditions
Transfusional Iron Overload, Beta-thalassemia
Interventions
SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Combination Iron Chelation Therapy

NCT00004982
View directory record Official record
Conditions
Iron Overload, Thalassemia
Interventions
Combination Iron Chelation Therapy
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Sep 25, 2026, 8:08 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556
View directory record Official record
Conditions
Thalassemia Major
Interventions
DST-0509, Jadenu, Exjade
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
8 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy (TACT)

NCT00044213
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
EDTA, EDTA Placebo, High Dose Vitamin, High Dose Vitamin Placebo
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
73
States / cities
Little Rock, Arkansas • Danville, California • Fresno, California + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

NCT02907359
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
Guadecitabine, Treatment Choice
Drug · Other
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 25, 2026, 8:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transfusion of Older Stored Red Cells

NCT01534676
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Transfusion, Blood, Chelation therapy
Procedure · Biological
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 25, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT06784336
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant
Interventions
Iron chelation, Potato Resistant Starch
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

NCT00303329
View directory record Official record
Conditions
Anemia, Hemosiderosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Oakland, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
View directory record Official record
Conditions
Myelodysplastic Syndrome, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 25, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

NCT02435212
View directory record Official record
Conditions
Transfusion-dependent Anemia
Interventions
Deferasirox granule formulation, Deferasirox DT formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Oakland, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 8:08 AM EDT